The CHST11 antibody targets the carbohydrate sulfotransferase 11 (CHST11) enzyme, a member of the sulfotransferase family involved in the sulfation of glycosaminoglycans (GAGs). CHST11 catalyzes the transfer of sulfate groups to chondroitin, a critical step in the biosynthesis of chondroitin sulfate (CS), a major component of extracellular matrices. This sulfation modulates CS interactions with growth factors, cytokines, and cell surface receptors, influencing cellular signaling, adhesion, and tissue development. CHST11 is highly expressed in cartilage, bone, and connective tissues, playing a key role in skeletal development, joint homeostasis, and tumorigenesis. Dysregulation of CHST11 has been linked to osteoarthritis, cancer metastasis, and developmental disorders due to altered sulfation patterns affecting cell-matrix interactions. Antibodies against CHST11 are widely used in research to investigate its expression, localization, and function in normal and pathological conditions. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding studies in cancer biology, cartilage repair, and genetic diseases. Commercial CHST11 antibodies are typically raised in rabbits or mice, with validation in specific applications. Understanding CHST11's role through antibody-based studies provides insights into therapeutic strategies targeting GAG sulfation pathways in disease contexts.